Atorvastatin is indicated for:
Population group: both men and women, only adults (18 years old or older)
Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Atorvastatin is indicated as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (Corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other nonpharmacological measures is inadequate.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: both men and women, only adults (18 years old or older)
Atorvastatin is also indicated to reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Atorvastatin is contraindicated in the following cases: